Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets

Share Article

The molecular diagnostics market is categorized on the basis of application, technology, end user, product, and geography.



Becton, Dickinson & Company (U.S.), Siemens Healthcare (Germany), bioMérieux (France), Abbott Laboratories (U.S.), Novartis AG (Switzerland), Cepheid (U.S.), and Beckman Coulter (U.S.)

The “Molecular Diagnostic Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), & by Product (Instruments, Reagent, Service, Software) - Global Forecast to 2018” provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global molecular diagnostics market along with the estimates and forecasts of the revenue and share analysis.

The global molecular diagnostics market will reach $7,956.9 million by 2018, growing at a CAGR of 9.7% during the forecast period (2013–2018).

From an insight perspective, this research report focuses on the qualitative data; market size, share, and growth of various segments and sub-segments; competitive landscape; and company profiles. The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats) and technological trends, globally. It also focuses on the emerging and high-growth segments of the molecular diagnostics market and the initiatives of their respective governments.

Speak to Analyst for More Info at

Molecular diagnostics (MDx) has emerged as one of the largest and fastest growing segments in the In Vitro Diagnostic (IVD) industry. In the span of few years, molecular diagnostics has prospered from a non-existent market to a significant market. PCR tests such as the one from Roche for CT/NG and other tests such as HIV qualitative and HIV quantitative (viral load) are the key factors driving the expansion of the molecular diagnostics market. The private reference laboratories developed tests for infectious diseases and cancer mutations due to the rising incidences and the non-availability of FDA approved assays. The market began to expand due to the existence of different diagnostic kits for genetic diseases and the blood screening for various infectious diseases. The demand for molecular testing increased and the FDA approved molecular diagnostic tests for determining genetic variation responses against cancer drugs. As a result, molecular diagnostic testing is growing at a rapid rate due to the rising adoption of rapid and quick diagnosis.

The reagents product segment accounted for the largest share of the total molecular diagnostics market in 2013 and will continue to grow in the next five years to retain its leading position. The high growth in this segment is attributed to the growing demand for molecular assays. Moreover, the rising incidences of infectious diseases such as HBV, HIV, CT/NG, and MRSA have also contributed to the largest share of the reagents market. The hospitals end user segment accounted for the second largest share in 2013. This segment can monitor various physiological parameters of a patient in order to have an overview of the patients’ health and status. Due to the tremendous increase in the number of infectious diseases, hospitals are increasing their investments in molecular diagnostic testing.

The PCR technology segment, on the other hand, will be the fastest growing segment in the coming years due to the evolution in technology that helps in diagnosis of various diseases. With the growing incidences and increasing awareness of various diseases this market is set to grow at a faster pace. Under this segment, the INAAT segment is also expected to grow at a higher pace in the forecast period. The microarray technology is also expected to be among the fastest growing in all other segments of the molecular diagnostics market.

In 2013, North America accounted for the largest share and will retain its leading position by 2018. This growth is attributed to the increasing prevalence of lifestyle diseases and spread of various contagious diseases. Asia is the most lucrative region for molecular diagnostics in the next five years, and is poised to grow at a CAGR of 12.2% in the forecast period. The high population base and the improved purchasing power of patients will drive this market. Moreover, the economic crisis in western countries has propelled the companies to focus on the Asian region, thus leading to the economic growth and rise in the investments in this region, which is further driving the market in a positive direction.

Get Inquiry For Further Details at

Asia is the most promising region for molecular diagnostics in the coming five years. It is expected to grow at a higher CAGR than North America and Europe over the forecast period. The high population base and improved purchasing power of patients are the major drivers of this market. Moreover, the economic instability in the western countries enables companies to focus on the Asian region in order to meet their revenue targets.

The grey area while estimating the market size was the overlapping nature of the applications segment and while segregating them based on the evaluation of endpoints involved. This was later clarified with the help of various experts that participated in the study.

The competitive landscape covers the growth strategies adopted by the industry players in the last three years. The company profiles comprises of the basic views on the key players in the molecular diagnostics market and their product portfolios, developments, and strategies adopted to maintain and increase their market share in the near future.

The key players in the molecular diagnostics market are Roche Diagnostics (Switzerland), Gen-Probe (Hologic) (U.S.), QIAGEN (Netherlands), Becton, Dickinson & Company (U.S.), Siemens Healthcare (Germany), bioMérieux (France), Abbott Laboratories (U.S.), Novartis AG (Switzerland), Cepheid (U.S.), and Beckman Coulter (U.S.).

About MarketsandMarkets

MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-600-6441
Email: sales(at)marketsandmarkets(dot)com
Visit MarketsandMarkets Blog at
Connect with us on LinkedIn at

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Mr. Rohan
since: 04/2009
Follow >
Market Research Report
Like >
Visit website